Abstract
Mammalian β-defensins are small cationic peptides that have been implicated in mediating innate immune defenses against microbial infection. Mouse β-defensin-14 (MBD-14), based on structural and functional similarities, appears to be an ortholog of human β-defensin-3 (HBD-3). Previous studies identified signaling pathway p38 mitogen-activated protein kinase (MAPK) that contributed to the expression of MBD-14 in mouse osteoblasts upon contacted with methicillin-resistance Staphylococcus aureus (MRSA) supernatant, which provided a theoretical basis as a promising therapeutic target in the treatment of intramedullary infection with MRSA in vivo. In this study, the medullary cavities of tibiae were contaminated with MRSA 103 colony forming units and different doses of p38 MAPK agonists anisomycin were followed as group III or IV in 30 mice. Fifteen animals that received phosphate- buffered saline served as group II and 15 mice were not contaminated with MRSA and received phosphate-buffered saline served as controls (group I). Follow-up was 7 days. In day 1, day 4 and day 7 postoperatively, infection was evaluated by blood routine, microbiological and histological analyses after sacrifice. All animals of group II developed microbiological and histological signs of infection. Histological signs of infection, white blood counts and cultures of group III and IV showed significantly reduced bacterial growth compared to cultures of group II. Simultaneously, different doses of anisomycin significantly induced the expression of osteoblast-associated genes, including alkaline phosphatase, osteocalcin and collagen type I. In addition, the expression of HBD-3 in human interfacial membranes around infected periprosthetic joint by staphylococcus contaminated was evaluated, and the expression pattern changed with significant induction of HBD-3 in infected periprosthetic joint compared with aseptic loosening under inflammatory conditions. Our primary study indicated that the potential antibacterial role of increased MBD-14 in the osteomyelitis mouse model.
Highlights
The rate of infection following orthopaedics is low, but the treatment of osteomyelitis or bone infections are still difficult in clinical practice [1]
In this study, the efficacy of anisomycin to increase the release of Mouse b-defensin-14 (MBD-14) and inhibit bacteria growth was evaluated in a mouse osteomyelitis model
Mouse medullary cavity was contaminated with ATCC 43300 which is characterized by their high affinity to bone, their rapid induction of osteonecrosis, and resorption of bone matrix [41]
Summary
The rate of infection following orthopaedics is low, but the treatment of osteomyelitis or bone infections are still difficult in clinical practice [1]. Antimicrobial prophylaxis, including the systemic and local use of antibiotics, has proven to be valuable in the prevention of bone infection in clinical use [6]. The global spread of MRSA is a matter of great concern in the treatment of staphylococcal infection, since it has rapidly acquired resistance to many clinical antibacterial agents [9]. More effective antimicrobial agents for systemic or local prophylaxis or treatment against these antibiotic-resistant organisms must be investigated. In light of this situation, antimicrobial peptides are attractive candidates as therapeutic agents for bacterial infections because of their selectivity, speed of action, relative difficulty in production of resistant mutants, and inherent immunological compatibility [10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
